Das J, et al. The use of autologous haematopoietic stem cell transplantation as a first line disease modifying therapy in patients with 'aggressive' multiple sclerosis. ECTRIMS 2018, abstract 230.
Vergoeding selumetinib (Koselugo) voor kinderen met neurofibromatose type 1
mei 2024